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Abstract
 
The B cell receptor (BCR) regulates B cell development and function through immunoglobu-
lin (Ig)
 
a
 
 and Ig
 
b
 
, a pair of membrane-bound Ig superfamily proteins, each of which contains a
single cytoplasmic immunoreceptor tyrosine activation motif (ITAM). To determine the func-
tion of Ig
 
b
 
, we produced mice that carry a deletion of the cytoplasmic domain of Ig
 
b
 
 (Ig
 
bD
 
C
mice) and compared them to mice that carry a similar mutation in Ig
 
a
 
 (MB1
 
D
 
C, herein re-
ferred to as Ig
 
aD
 
C mice). Ig
 
bD
 
C mice differ from Ig
 
aD
 
C mice in that they show little impair-
ment in early B cell development and they produce immature B cells that respond normally to
BCR cross-linking as determined by Ca
 
2
 
1
 
 flux. However, Ig
 
bD
 
C B cells are arrested at the
immature stage of B cell development in the bone marrow and die by apoptosis. We conclude
that the cytoplasmic domain Ig
 
b
 
 is required for B cell development beyond the immature B
cell stage and that Ig
 
a
 
 and Ig
 
b
 
 have distinct biologic activities in vivo.
Key words: B cell receptor • immunoglobulin 
 
a
 
 • immunoglobulin 
 
b 
 
• immunoreceptor 
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Introduction
 
Signals from the B cell receptor (BCR)
 
1
 
 regulate many of
the essential physiologic activities in the B cell pathway.
These include several different transitions in B cell devel-
opment, allelic exclusion, central and peripheral tolerance,
as well as B cell survival and response to antigen (1). All of
these functions appear to be induced by signals emanating
from the Ig-associated heterodimer of Ig
 
a
 
 and Ig
 
b
 
 (2–4).
Signals initiated by ligand binding to membrane (m)IgM
are communicated to the Ig
 
a
 
–Ig
 
b
 
 transducer through a
noncovalent interaction that involves polar residues in the
plane of the cell membrane (5–7). Mutations that disrupt
these polar residues interfere with signal transduction and
early B cell development (5–8).
The discovery that the BCR signal transducer is a het-
erodimer led to the proposal that the Ig
 
a
 
 and Ig
 
b
 
 subunits
might have distinct biological functions. Biochemical stud-
ies showing that the cytoplasmic tails of Ig
 
a
 
 and Ig
 
b
 
 bind
to different sets of cellular kinases (9) and transfection ex-
periments showing differences in the signaling activities of
Ig
 
a
 
 and Ig
 
b
 
 cytoplasmic domains support this idea (6, 7,
10–14). However, experiments performed in mice have
failed to show any differences in the biologic activities of
Ig
 
a
 
 and Ig
 
b
 
. Similarly, there are no known qualitative dif-
ferences in the activities of any of the immunoreceptor ty-
rosine activation motifs (ITAMs) in the CD3 chains of the
TCR (15–21).
Three approaches have been used to determine the func-
tion of Ig
 
a
 
 and Ig
 
b
 
 in vivo: transgenic expression of chi-
meric proteins (8, 22, 23), Ig
 
b
 
 gene deletion (24), and Ig
 
a
 
cytoplasmic tail mutation (25). Transgenic experiments
showed that the cytoplasmic domain of either Ig
 
a
 
 or Ig
 
b
 
was sufficient to activate allelic exclusion and pre-B cell de-
velopment and led to the conclusion that Ig
 
a
 
 and Ig
 
b
 
 are
redundant in early B cell development (8, 22, 23). Deletion
of Ig
 
b
 
 resulted in B cells that failed to assemble a BCR and
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Ig
 
b
 
 Cytoplasmic Tail Truncation
 
were arrested at the pre-BI cell stage, suggesting that BCR
assembly is essential for B cell development (24). Deletion
of 40 of the 61 cytoplasmic amino acids of Ig
 
a
 
, including
both ITAM tyrosines (Ig
 
aD
 
C [25]), produced B cells that
assembled a mutant BCR composed of mIg
 
m
 
 and an Ig
 
a
 
–
Ig
 
b
 
 heterodimer with a truncated Ig
 
a
 
 tail. In agreement
with the transgenic experiments, the single Ig
 
b
 
 cytoplasmic
domain in the Ig
 
aD
 
C BCR was enough to induce pre-B
cell development and allelic exclusion (8, 25). However,
the number of pre-B cells in Ig
 
aD
 
C mice was reduced by
50%, immature B cells were reduced by 80%, and the
number of mature B cells in spleen was only 1% of control.
Thus, a BCR with only an Ig
 
b
 
 cytoplasmic domain was
unable to support later stages of B cell development. Fur-
thermore, increased tyrosine phosphorylation in Ig
 
aD
 
C B
cells and increased calcium flux in response to receptor
cross-linking suggested a unique negative regulatory role
for the Ig
 
a
 
 cytoplasmic domain (26, 27).
To compare the biologic function of Ig
 
a
 
 and Ig
 
b
 
 di-
rectly, we produced mice that carry a targeted deletion of
the cytoplasmic domain of Ig
 
b
 
.
 
Materials and Methods
 
Mice.
 
Ig
 
bD
 
C mice were created by gene targeting in 129/Sv
embryonic stem cells (24). To shorten the cytoplasmic tail of Ig
 
b
 
by 45 amino acids and delete the ITAM, the stop codon TGA
was introduced by PCR at amino acid 184 (4). A unique HindIII
site was placed into the targeting vector between the exons as in-
dicated (see Fig. 1 A). A lox-P–flanked neomycin resistance gene
was inserted between two XbaI sites, and sequence coding for
diphtheria toxin (DTA [28]) was added to the 3
 
9
 
 end of the tar-
geted locus at the XhoI site (see Fig. 1 A). Homologous recombi-
nation was confirmed by Southern blotting after digestion with
HindIII (see Fig. 1 B). The rate of homologous recombination
was 1:80. The genomic fragment used as a probe for Southern
blotting was amplified by PCR using the specific primers GGAT-
TCGAATGGTGAATGTTGG and AGGCTCTAGCTCAGT-
GAAGGGAG. PCR conditions were: 94
 
8
 
C for 5 min, and 30
cycles of 94
 
8
 
C for 30 s, 48
 
8
 
C for 45 s, and 72
 
8
 
C for 1 min, fol-
lowed by extension at 72
 
8
 
C for 7 min. To delete the neomycin
gene, mice carrying the targeted Ig
 
b
 
 gene were bred to C57BL/6
Cre transgenic mice (29). Deletion of the neomycin gene was
confirmed by PCR using neomycin-specific primers ATGAT-
TGAACAAGATGGATTGCAC and TCGTCCAGATCATC-
CTGATCGAC. PCR conditions were: 94
 
8
 
C for 3 min, and 30
cycles of 94
 
8
 
C for 1 min, 58
 
8
 
C for 45 s, and 72
 
8
 
C for 1 min, fol-
lowed by extension at 72
 
8
 
C for 7 min. Heterozygous Ig
 
bD
 
C
mice were backcrossed to C57BL/6 mice for three generations
before intercrossing to produce homozygous Ig
 
bD
 
C mice. All
mice were bred and maintained under specific pathogen–free
conditions.
Ig
 
aD
 
C mice (25) were crossed with Ig
 
bD
 
C mice to create Ig-
 
aD
 
C/Ig
 
bD
 
C mixed heterozygous and homozygous mice (25).
Ig
 
bD
 
C mice were also bred to C57BL/6 Ig
 
HEL
 
 Ig transgenic mice
(30).
 
Flow Cytometry.
 
Single cell suspensions from bone marrow,
spleen, and peritoneal cavity were stained with FITC, PE, allo-
phycocyanin, and biotin-conjugated monoclonal antibodies visu-
alized with streptavidin red 613 (GIBCO BRL). Monoclonal
antibodies were anti-CD43, anti-IgM, anti-B220, anti-CD25, anti-
 
IgD, anti-CD19, anti-IgM
 
a
 
, anti-IgM
 
b
 
 (BD PharMingen), biotin
anti-Ig
 
b
 
 (a gift from H. Karasuyama, The Tokyo Metropolitan
Institute of Medical Science, Tokyo, Japan), and anti-493 (a gift
from A. Rolink, Basel Institute for Medical Science, Basel, Swit-
zerland). For intracellular Ig
 
m
 
 staining, cells were first surface
stained with anti-B220–allophycocyanin, anti-CD25–PE, and/or
anti-IgM–PE, and anti-CD43–biotin, permeabilized with Intra-
prep permeabilization kit (Immunotech), and incubated with
Fab
 
9
 
 fragments of FITC-goat anti–mouse IgM. Data were col-
lected on a FACSCalibur™ and analyzed using CELLQuest™
software (Becton Dickinson).
 
Cell Cycle Analysis.
 
Bone marrow cells were incubated at
37
 
8
 
C for 40 min with Hoechst 33342 (Molecular Probes) diluted
1:1,000, then stained for cell surface markers with anti-B220,
anti-IgM, anti-CD43, and anti-CD25. Data were collected on a
FACS Vantage™ and analyzed with CELLQuest™ software
(Becton Dickinson).
 
Ca
 
2
 
1
 
 Flux.
 
Bone marrow cells were adjusted to 5 
 
3
 
 10
 
6
 
/ml
in PBS plus 1% FCS plus 1 mM CaCl
 
2 
 
plus 1 mM MgCl
 
2 
 
(load-
ing buffer), and incubated with 1.5 
 
m
 
M Indo-1-AM (Molecular
Probes) for 30 min at 37
 
8
 
C. Cells were stained with PE–anti-
B220 and Fab
 
9
 
 FITC-goat anti–mouse IgM (Jackson Immu-
noResearch Laboratories). Calcium flux was measured by fluo-
rescence emission ratios of Indo-1-AM on a dual laser FACS
Vantage™ (Becton Dickinson) at 395/510 nm on B220
 
low
 
IgM
 
1
 
cells. Data were acquired for 60 s before BCR cross-linking with
F(ab
 
9
 
)
 
2 goat anti–mouse IgM (Southern Biotechnology Associ-
ates, Inc.) at 10 or 20 mg/ml.
B Cell Cultures. Bone marrow B cells from mutant or wild-
type mice were enriched by positive selection using MACS
mouse CD19 microbeads (Miltenyi Biotech) and stained with
Fab9 anti-IgM, and monoclonal anti-CD25, anti-CD43, and
anti-B220. B cells were then sorted into B2201CD432IgMlow
immature B cells and cocultured at 106/ml with irradiated S17
stromal cells in RPMI 1640 supplemented with 10% FCS and 10
ng/ml IL-7 (BD PharMingen [31]). B cell viability was assessed
on days 0 and 1 by flow cytometry using PE–annexin V (BD
PharMingen) and propidium iodide staining.
Immunization. 6–8-wk-old IgbDC and C57BL/6 mice were
immunized intraperitoneally with either 50 mg alum-precipitated
4-hydroxy-3-nitrophenylacetyl coupled to chicken gamma glob-
ulin (NP-CGG) or 50 mg NP-Ficoll in PBS. Blood was collected
from the tail vein of each mouse before immunization and at days
7, 14, 21, and 28 after immunization. NP-specific IgM and IgG
levels were measured by ELISA using plates coated with
NP16BSA (5 mg/ml) and developed with anti-IgM coupled to
horseradish peroxidase or anti-IgG coupled to horseradish perox-
idase (Southern Biotechnology Associates, Inc. [32]). Immunoab-
sorbance was read at 415 nm and titers were calculated relative to
control sera from unimmunized mice. Four mice were used in
each group.
Results
B Cell Development in IgbDC Mice. Gene targeting was
used to introduce a stop codon at position 184 in Igb (Fig.
1 A). The mutant gene directs the expression of a truncated
Igb protein that resembles mIgm in having only three
charged cytoplasmic anchor amino acids (DKD).
B cell development in IgbDC mice was analyzed by mul-
tiparameter flow cytometry. When compared with wild-
type controls, IgaDC and IgbDC mice showed an increase15 Reichlin et al.
in the number of IgM2B2201CD431CD252 pro-B cells
(25; Table I and Fig. 1 C). Both strains also showed smaller
numbers of IgM2B2201CD432CD251 pre-BII cells (frac-
tion C9/D) than wild-type, although the 25% decrease
found in IgbDC mice was less substantial than the 50% de-
crease found in IgaDC mice (25; Table I and Fig. 1 C).
After H chain expression, pre-BI cells become large di-
viding pre-BII cells (fraction C9 [33–36]). To determine
whether the single Iga cytoplasmic domain in the IgbDC
BCR is sufficient to trigger normal pre-BII cell division,
we measured the DNA content of these cells. We found
that the cell cycle distribution of large pre-BII cells in Ig-
bDC mice was similar to that of control mice (Fig. 1 C and
Table I). Thus, the single cytoplasmic tail of Iga in the Ig-
bDC BCR is sufficient to trigger pre-BII cell (fraction C9)
proliferation.
After mIgm triggered proliferative expansion, B cells re-
arrange Ig L chain genes, express surface IgM, lose CD25
expression, and then express IgD (37). Few B cells in Ig-
aDC mice progress to the B2201CD432IgM1IgD2 “im-
mature” B cell stage (fraction E) (25; Fig. 1 C, second row;
B2201CD432 gated IgM histograms; IgM versus CD25,
B220 versus IgM, and IgM versus IgD dot plots). In con-
trast, IgbDC B cells proceed to this immature B cell stage
in normal numbers, although the level of IgM expressed
on the cell surface is lower than control (Fig. 1 C). Imma-
ture IgbDC B cells fail to progress further to the
CD252IgM1IgD1 transitional B cell stage (Fig. 1 C; IgM
Figure 1. IgbDC gene targeting. (A) Scheme for IgbDC gene targeting showing the genomic Igb locus (top), targeting vector (middle), and recombi-
nant locus after deletion of the neo gene (bottom). Exons are represented by open boxes, loxP sites by open triangles, and the exon containing the mu-
tant stop codon at position 184 by a filled box. The probe used to identify homologous recombinants is shown. (B) Southern blot analysis of wild-type,
homozygous, and heterozygous mice. HindIII digestion of genomic DNA yields restriction fragments of 4 or 9 kb corresponding to targeted or wild-type
alleles, respectively. (C) Analysis of bone marrow B cells in wild-type (Wt), IgaDC, and IgbDC mice. In B220 vs. CD43 and B220 vs. IgM plots, num-
bers indicate the percentages of lymphocytes determined by forward versus side scatter parameters. In IgD vs. IgM and IgM vs. CD25 plots, numbers in-
dicate the percentages of B2201 cells in the boxed region. In the IgM histograms, numbers indicate the percentage of B2201CD432 that are IgM positive
(immature B cells). IgD vs. IgM, IgM vs. CD25, and Igb vs. IgM dot plots show bone marrow cells that were pregated on B2201 cells. DNA content is
shown through Hoechst 33342 staining of large B2201CD251 pre-B cells, and the percentage of cells in S and G2/M phase is indicated. (D) Analysis of
spleen B cells in wild-type (Wt), IgaDC, and IgbDC mice. Spleen plots for IgaDC and IgbDC mice show a fivefold greater number of events than the
wild-type. Antibodies used for staining are indicated. 16 Igb Cytoplasmic Tail Truncation
versus CD25, B220 versus IgM, and IgM versus IgD). Fail-
ure to progress to the CD252IgM1IgD1 transitional B cell
stage is reflected in the near absence of recirculating B cells
in the bone marrow and mature B cells in spleen (Fig. 1, C
and D). To determine whether this failure to mature is due
to low levels of surface Iga–Igb expression, we stained de-
veloping B cells with anti-Igb monoclonal antibody (38).
We found that for any given level of surface IgM expres-
sion, the level of cell surface Igb on B2201IgM1 immature
B cells was similar in IgbDC B cells and controls (Fig. 1 C).
Thus, IgaDC mice suffer a continuous loss of B cell pre-
cursors beginning at the pre-B cell stage, whereas B cell de-
velopment is terminated abruptly at the immature B cell
stage in IgbDC mice (25; Fig. 1 C and Table I).
To determine whether arrest at the CD251IgM1IgD2
immature B cell stage is associated with increased cell death,
we established in vitro bone marrow cultures (31). Imma-
ture B cells were purified by cell sorting using a Fab9 anti-IgM
to avoid receptor cross-linking. Cell death was measured by
propidium iodide exclusion and annexin V staining (Fig. 2).
Annexin V staining varies between different stages of B cell
development and is therefore unreliable when comparing B
cells in different stages (39). However, annexin is a reliable
marker for apoptosis when comparing cells at similar stages
Table I. B Cell Development and Cell Cycle Analysis
Percentage of B2201 bone marrow cells Percentage of B2201 cells in S/G2/M
Pre-BI* Pre-BII‡ Immature§ Recirculatingi Pre-BII (small)¶ Pre-BII (large)**
C57BL/6 27 6 2.2 37 6 5.3 23 6 12.6 7.0 6 3.6 0.4 6 0.3 33 6 6.0
IgbDC 55 6 4.0 27 6 2.8 28 6 11.9 0.1 6 0.1 0.7 6 0.8 20 6 6.5
Data represent the mean from four mice 6 SD.
*CD431IgM2CD252.
‡CD432IgM2CD251.
§B220loCD432IgM1.
iB220hiCD432IgM1.
¶IgM2CD251.
**IgM2CD251.
Figure 2. B cell development and death in bone marrow
cultures. Bone marrow cells from IgbDC and control mice
were selected using CD19 MACS beads, sorted for
B2201CD432IgMlow immature B cells, and then cocul-
tured with S17 stromal cells. (A) Dot plots show staining
with anti-CD25 or anti-IgD and anti-IgM at the initiation
of culture (left) and after 24 h (right). Numbers indicate
percentages of B2201 cells in each quadrant. Wt, wild-type.
(B) Bar graphs show the percentage of B2201 cells that
were annexin V or propidium iodide. Results are the aver-
age of duplicate cultures performed on two independent
mice. The variation between samples and mice was ,5%.17 Reichlin et al.
in development (39). Freshly isolated immature IgbDC and
control B cells were equally viable as measured by exclusion
of propidium iodide. In culture, the control immature B
cells developed into CD252IgMhiIgD1 transitional B cells,
whereas the IgbDC B cells did not progress beyond the
CD251IgMloIgD2 immature B cell stage. Instead, IgbDC B
cells became increasingly annexin V and propidium iodide
positive (Fig. 2). Thus, IgbDC B cells that reach the
CD251IgM1IgD2 immature B cell stage fail to progress
and die by apoptosis.
Allelic Exclusion. In addition to supporting pre-B cell
development, cell surface expression of the BCR induces
Ig H chain allelic exclusion (40, 41). To determine
whether the single Iga cytoplasmic domain in IgbDC mice
is sufficient for allelic exclusion, we bred IgbDC mice to
IgHEL transgenic mice which carry an allotype marked Igma
H chain (30). IgHEL transgenic IgbDC mice resemble non-
transgenic IgbDC mice in that their B cells fail to progress
beyond the immature stage of B cell development, they ex-
press lower levels of surface IgM than controls, and there
are few detectable B cells in the spleen and the peritoneal
cavity (Fig. 3). Nevertheless, allelic exclusion is established
normally in IgHEL transgenic IgbDC B cells. 96% of the im-
mature B cells in the bone marrow of both IgHEL transgenic
IgbDC mice and control mice expressed the IgHEL Igma H
chain, whereas only 3–4% coexpressed the endogenous
Igmb H chains (Fig. 3). We conclude that the single Iga cy-
toplasmic domain in IgbDC BCRs is sufficient to maintain
H chain allelic exclusion and that transgenic antibody ex-
pression is not sufficient to induce further B cell differenti-
ation in IgbDC mice.
Peripheral B Cells and Antibody Responses. Splenic B cell
numbers were reduced to z2% in IgbDC mice in compar-
ison with wild-type controls (0.64 6 0.66 3 106 B cells,
n 5 5 versus 27.51 6 5.86 3 106 B cells, n 5 8). A similar
block in the development and maintenance of mature B
lymphocytes was present in IgaDC mice (splenic B cell
numbers are reduced to z1% [0.21 6 0.14 3 106, n 5 5;
reference 25). The maturation status of splenic B lympho-
cytes was examined in IgaDC and IgbDC mice. More than
80% of B lymphocytes did not stain for the immature B cell
marker 493 (42) and displayed a mature phenotype (data
not shown). We also examined splenic B cells for surface
expression of CD23 and MHC class II and found no effect
of the cytoplasmic truncations (data not shown). However,
peripheral B lymphocytes in IgaDC and IgbDC mice ex-
pressed higher levels of CD19 (Fig. 1 D). Splenic B cells in
IgaDC mice expressed normal levels of cell surface IgM. In
contrast, the splenic B cells found in IgbDC mice resem-
bled their bone marrow precursors and continued to ex-
press 10 times lower levels of surface IgM and 0.5 times
lower levels of IgD than controls (Fig. 1 D).
The scarce peripheral B cells in IgaDC mice produce
specific antibody responses to T cell–dependent but not to
T cell–independent antigens (25). To determine whether
IgbDC B cells can respond to antigens, we immunized
mice with T cell–dependent (NP-CGG) and T cell–inde-
pendent (NP-Ficoll) antigens and measured specific anti-
body responses by ELISA. IgbDC B cells mount a hapten
specific immune response to NP-CGG with class switching
Figure 3. B cell development
and allelic exclusion in IgbDC
IgHEL transgenic mice. In the
B220 vs. CD43 and B220 vs.
IgM plots, numbers indicate per-
centages of lymphocytes as de-
termined by forward vs. side
scatter parameters. In the IgD vs.
IgM plots, numbers indicate per-
centages of B2201 cells in the
boxed region. For H chain allelic
exclusion, dot plots show B cells
gated on B2201IgM1 cells
stained with IgMa and IgMb, and
the numbers indicate the per-
centage of B2201IgM1 cells in
each quadrant. B220 vs. IgM
staining in the spleen (Spl) and
peritoneal cavity (Per) is shown. 
Figure 4. Antibody responses in IgbDC mice. Plots show anti-NP
IgM and IgG responses measured by ELISA on days 7, 14, 21, and 28
after immunization with NP-CGG or NP-Ficoll. The open squares rep-
resent individual wild-type controls and the filled diamonds represent in-
dividual IgbDC mice. The y axis indicates OD415 relative to unimmu-
nized controls. The lines represent the means.18 Igb Cytoplasmic Tail Truncation
to IgG, but do not appear to respond to NP-Ficoll. Consis-
tent with the small number of peripheral B cells in the Ig-
bDC mice, anti-NP antibody titers were two orders of
magnitude lower than controls (Fig. 4). We conclude that
like IgaDC B cells, IgbDC B cells respond to T cell–depen-
dent but not T cell–independent antigens.
Ca21 Flux. Ca21 flux responses are enhanced in imma-
ture B cells from IgHEL transgenic, IgaDC mice (27). This
increase in the Ca21 response could be due to a unique
negative regulatory role for Iga in developing B cells or,
alternatively, to a difference in Ca21 responses induced by
IgHEL transgene expression in the IgaDC background (27).
To determine whether altered responses to BCR cross-
linking were IgaDC specific, we measured Ca21 flux in re-
sponse to BCR cross-linking in immature IgbDC bone
marrow cells. B cells expressing similar levels of surface
IgM were compared by electronically gating on surface
IgM expression after staining with an Fab9 anti-IgM. We
found no measurable differences in Ca21 responses to anti-
BCR cross-linking between immature IgbDC B cells and
control immature B cells (Fig. 5). In contrast, IgHEL trans-
genic IgbDC B cells produced a higher magnitude Ca21
response than either wild-type controls or IgHEL transgenic
B cells despite lower surface IgM expression (Fig. 5). We
conclude that cross-linking the BCR in immature IgbDC
B cells induces normal Ca21 flux responses, whereas B cells
in IgbDC mice carrying the IgHEL transgene have hyperac-
tive receptors.
B Cell Development in the Absence of Iga and Igb Tails.
To determine whether the cytoplasmic domain of either
Iga and Igb is essential for pre-B cell development, we
produced double mutant IgaDC/IgbDC mice by crossing
IgaDC and IgbDC mice. IgaDC/IgbDC mice resembled
Igb2/2 mice in that B cell development was arrested at the
B2201CD431CD252 pre-BI stage (24; Fig. 6 A). We con-
clude that B cell development cannot proceed beyond the
pre-BI stage in the absence of the cytoplasmic domains of
both Iga and Igb.
Mixtures of B2201CD431 pro- and pre-B cells purified
from Igb2/2 mice have fewer complete VDJH genes than
wild-type B2201CD431IgM2 pro- and pre-B cells (24).
This effect could be due to inefficient V to DJH recombina-
tion in pre-BI cells lacking Igb, or to lack of positive selec-
tion and amplification of pre-BII cells with in-frame Ig H
chains (24). To determine whether the cytoplasmic do-
mains of Iga and Igb are required for Ig H chain recombi-
nation and expression, we stained for intracellular Igm.
Developing B cells in IgaDC/IgbDC, Igb2/2, mMT, re-
combination activating gene (RAG)2/2, and wild-type
mice were compared after cell surface staining with anti-
B220, anti-CD43, anti-CD25, and anti-IgM to separate
pre-BI and pre-BII cell subpopulations, and intracellular
staining for Igm to measure H chain expression. Consis-
tent with previous reports, intracellular Igm levels in
B2201CD431IgM2 mixtures of pre-BI and pre-BII cells
were decreased in Igb2/2 mice compared with wild-type
controls (Fig. 6 B). IgaDC/IgbDC and mMT mice resem-
bled Igb2/2 mice in that their B2201CD431 cells also
showed lower levels of intracellular Igm expression than
controls. However, intracellular Igm levels in pre-BI cells
in IgaDC/IgbDC mice were similar to Igb2/2, mMT, and
wild-type controls (B2201CD431IgM2CD252 cells; Fig. 6
B). Therefore, the decreased Igm expression in the devel-
oping B cells in these mutant strains is due to arrest at the
pre-BI stage and lack of positive selection for B cells with
an in-frame Ig H chain during pre-BII cell expansion. We
conclude that the cytoplasmic domains of Iga and Igb are
essential for B cell development past the pre-BI stage, and
that IgaDC/IgbDC, Igb2/2, and mMT are all arrested at a
similar stage in development.
Discussion
Iga or Igb Signaling Is Essential for Pre-B Cell Develop-
ment. We have shown that the cytoplasmic domain of ei-
ther Iga or Igb is essential for B cells to develop beyond
the pre-BI (fraction B/C) stage. In the absence of BCR as-
sembly, RAG2/2 (43, 44), Igb2/2 (24), and mMT (33) B
cells all fail to progress beyond the pre-BI stage. Although
it has been assumed that this early block in development is
Figure 5. Ca21 flux response to BCR cross-linking in immature B cells
in IgbDC and IgHEL transgenic IgbDC mice. Dot plots represent Ca21
flux of immature B cells measured by the fluorescence 395/510 nm ratio
of Indo-1-AM emission accumulated over 512 s. Immature B cells were
gated by staining with anti-B220 and Fab9 anti-IgM fragment. Baseline
fluorescence was acquired for 60 s before the agonist, F(ab9)2 goat anti–
mouse IgM at a final concentration of either 10 or 20 mg/ml, was added.
Wt, wild-type.19 Reichlin et al.
due to failure to activate a BCR-dependent checkpoint, it
might also be due to aberrant expression of BCR compo-
nents. For example, expression of Igm and Iga in the ab-
sence of Igb in Igb2/2 mice produces an incomplete re-
ceptor that is not transported to the cell surface and might
be toxic for developing pre-B cells. Similarly, only very
low levels of Iga–Igb are expressed on the cell surface in
the absence of mIgm in RAG2/2 B cells (45). In contrast,
the combination of IgaDC and IgbDC mutations produces
surface BCRs that are simply unable to signal. Therefore,
the finding that IgaDC/IgbDC B cells arrest at the pre-BI
stage shows that the cytoplasmic domain of either IgaDC
or IgbDC is essential for early B cell development, and that
BCR signaling as opposed to assembly is required for later
stages of B cell development.
B Cell Development Differs in IgaDC and IgbDC Mice.
Many aspects of B cell development are similar in IgaDC
and IgbDC mice. For example, pre-B cell development and
allelic exclusion are activated in both strains, and there are
few peripheral B cells in either. However, the two strains
differ in that B cells are lost throughout development in Ig-
aDC mice, whereas significant B cell loss is not apparent in
IgbDC mice until the late stages of B cell maturation. Ig-
bDC B cell development is arrested before high level sur-
face IgM expression and acquisition of surface IgD. Low
surface IgM expression is not characteristic of IgaDC mice
and appears to be specific for IgbDC, suggesting that the cy-
toplasmic domain of Igb plays an important role in regulat-
ing surface BCR expression. Alternatively, the single Iga
molecule may interfere with receptor assembly or enhance
receptor degradation in IgbDC mice. Failure to acquire
high levels of surface IgM is not due to an intrinsic defect in
BCR expression, as there is a broad spectrum of IgM ex-
pression in the selected B cells found in the spleen of IgbDC
mice including B cells that express high levels of surface
IgM. Indeed, the heterogeneity of BCR surface expression
suggests that antibody specificity contributes to setting the
level of BCR expression in IgbDC mice. We would like to
speculate that decreased surface BCR expression is a conse-
quence of altered BCR signaling in IgbDC B cells.
The differences in B cell development between IgaDC
and IgbDC mice are reminiscent of the differences in sig-
naling between Iga and Igb chimeras in transfected cell
lines. B and T cell lines transfected with Iga chimeras
Figure 6. Cytoplasmic domains of Iga and Igb are essential for B cell development. (A) Dot plots show staining with combinations of anti-B220, anti-
CD43, anti-IgM, and anti-CD25 antibodies in bone marrow and spleen. In the B220 vs. CD43 and B220 vs. IgM plots, numbers indicate percentages of
lymphocytes as determined by forward vs. side scatter parameters. In the IgM vs. CD25 plots, numbers indicate percentages of B2201 cells in the boxed
region. Wt, wild-type. (B) Intracytoplasmic Igm expression in IgaDC/IgbDC, Igb2/2, mMT, RAG2/2, and wild-type mice. Dot plots show staining
with anti-B220 and anti-CD43, and the boxed region was used in further gating as indicated. Histograms show intracytoplasmic Igm staining in surface
B2201CD431IgM2 pro- and pre-B cells and B2201CD431IgM2CD252 pre-BI cells. Numbers indicate the percentages of intracellular Igm1 surface
B2201CD431IgM2 pro- and pre-B cells and B2201CD431IgM2CD252 pre-BI cells.20 Igb Cytoplasmic Tail Truncation
showed higher levels of signaling than those transfected
with Igb chimeras (6, 7, 10–14). Furthermore, in some cell
lines, chimeric receptors required both Iga and Igb cyto-
plasmic domains to trigger cell death (13). However, the
differences in the IgaDC and IgbDC mice were unex-
pected because transgenic mice that carry Igm–Iga or Igm–
Igb chimeric receptors showed equivalent function in early
(8, 22) and late stages of development (23). Furthermore,
in both Igm–Iga or Igm–Igb transgenics, B cells developed
fully and left the bone marrow whereas IgaDC and IgbDC
mice show few mature B cells in the spleen (23). Several
differences between the chimeric antibody transgenics and
IgaDC and IgbDC mice could account for these apparent
discrepancies. First, the transgenic mice carried artificial re-
ceptors in which the tails of Iga or Igb were grafted onto
heterologous transmembrane and external domains (8, 22,
23). Second, the genes coding for the transgenic receptors
were controlled by Ig regulatory elements in multicopy
randomly integrated loci and therefore the regulation of
expression was not that of endogenous Iga and Igb. Fi-
nally, the transgenic receptors carried dimers of Iga or Igb
tails instead of the normal monomers and therefore had
twice as many signaling ITAMs as the BCRs in IgaDC and
IgbDC mice.
Experiments performed on TCR CD3 proteins suggest
that the ITAM-containing cytoplasmic domains of g, e, d,
and z proteins are functionally equivalent and that multiple
ITAMs merely amplify signal strength (15–21). However,
the TCR is a complex with 4 signaling proteins containing
10 ITAMs, and the role of individual ITAMs in T cell
function has not been fully explored. In contrast to the
TCR, the BCR has only two transducers, each with a sin-
gle ITAM, and therefore differences between IgaDC and
IgbDC mice cannot simply be due to a difference in the
number of ITAMs (46).
These differences in signaling between Iga and Igb may
be attributed to the two additional non-ITAM tyrosines in
the cytoplasmic domain of Iga (nos. 204 and 176; refer-
ences 2 and 46). Neither of these tyrosine residues is
known to be phosphorylated upon BCR cross-linking.
Nevertheless, the sequence around tyrosine 204, YDQV,
conforms to a consensus src homology 2 (SH2) docking
site (47), and the acidic residues surrounding tyrosine 176
resemble those found in the cytoplasmic domain of eryth-
rocyte band 3 protein, a target of ptk72 (48). Therefore, ty-
rosine 204 and 176 in Iga may recruit a distinct set of SH2
domain–containing signaling proteins, or simply enhance
signaling through Iga by increasing the number of SH2
docking sites on Iga. Other differences between Iga and
Igb that could account for the differences in signaling in-
clude higher levels of serine and threonine phosphorylation
on Igb (9) and nonconserved residues between the ty-
rosines in the ITAMs of Iga and Igb that appear to modu-
late src kinase binding (49).
An additional distinction between IgaDC and IgbDC
mice is that the Iga tail truncation created by Torres et al.
(25) shortened the cytoplasmic tail of Iga by 40 amino ac-
ids leaving 21 amino acids, including one non-ITAM ty-
rosine intact. Our strategy shortened the Igb cytoplasmic
tail by 45 amino acids, leaving a 3 amino acid anchor,
DKD. The considerably longer remaining cytoplasmic se-
quence in the Iga tail truncation may have some signaling
function beyond that attributable to the ITAM sequence.
Thus, there may be an even greater difference between a
complete Iga and Igb tail truncation.
Hyperresponsive BCRs in IgbDC IgHEL Transgenic B
Cells. The hyperresponsive phenotype found in IgbDC
IgHEL transgenic mice resembles the effects found in IgHEL
transgenic Src homology 2 domain–containing phos-
phatase 1 (SHP1) and lyn-deficient mice (50, 51). In the
absence of these negative regulators, B cells are hyperre-
sponsive to BCR cross-linking. Therefore, one explana-
tion for the hyperreactive phenotype in IgaDC and IgbDC
IgHEL transgenic B cells might be that their BCRs are un-
able to recruit negative regulators of signal transduction
such as SHP1 and lyn.
In contrast to IgbDC IgHEL transgenic B cells, nontrans-
genic IgbDC B cells are indistinguishable from controls in
Ca21 flux experiments. Thus, the hyperactive phenotype
appears to be Ig transgene specific. The discrepancy be-
tween IgbDC IgHEL transgenic B cells and nontransgenic
IgbDC B cells could be due to partial compensation for ab-
normal B cell development in IgbDC mice by the IgHEL
transgene. Alternatively, the difference between transgenic
and nontransgenic B cells could be due to artificially accel-
erated and altered B cell development in the transgenic
mice.
A unique negative regulatory role for Iga was suggested
by experiments with IgaDC mice (26, 27). However, Ig-
bDC IgHEL transgenic B cells resemble IgaDC IgHEL trans-
genic B cells in that they too were hyperresponsive com-
pared with IgHEL controls in Ca21 flux experiments. Thus,
the absence of either Iga or Igb produces a hyperreactive
IgHEL transgenic B cell and this negative regulatory effect is
not specific for Iga or Igb.
Arrested B Cell Development in IgbDC Mice. Several
mutations in signaling molecules and B cell coactivators
have phenotypes similar to IgbDC. In humans, Btk muta-
tion interferes with B cell development at several stages,
beginning at the pre-B cell stage resulting in a near absence
of peripheral B cells (X-linked agammaglobulinemia [52–
54]). In mice, Btk mutation results in a four- to fivefold de-
crease in the number of recent bone marrow emigrants. Al-
though the number of mature B cells is near normal, T
cell–independent responses are severely diminished in these
mice (55–58). Phosphoinositide 3-kinase deficiency in
mice resembles Btk mutation in that there are decreased
numbers of mature peripheral B cells and decreased levels
of serum Ig (59, 60). Mouse mutations in B cell coreceptors
CD22 (61, 62), CD19 (63, 64), the lyn kinase (65), and the
CD45 phosphatase (66) all interfere with B cell develop-
ment at the immature to mature B cell transition, but these
effects are more subtle and less specific than the block in B
cell development seen in IgbDC mice.
Immature B cells are highly susceptible to deletion in-
duced by BCR cross-linking, a feature which is likely to21 Reichlin et al.
contribute to B cell tolerance by removing cells with self-
reactive receptors (67, 68). Our work shows that this
checkpoint is regulated by Iga–Igb and that Igb plays a
particularly important role in setting the threshold for B
cell development beyond the immature B cell stage.
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